Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2017, Article ID 3204504, 7 pages
https://doi.org/10.1155/2017/3204504
Clinical Study

The Effects of Melatonin on Elevated Liver Enzymes during Statin Treatment

1Department of Clinical Nutrition and Gastroenterological Diagnostics, Medical University, Lodz, Poland
2Department of Gastroenterology, Medical University, Lodz, Poland

Correspondence should be addressed to Jan Chojnacki; lp.zdol.demu@ikcanjohc.naj

Received 1 February 2017; Accepted 26 March 2017; Published 29 May 2017

Academic Editor: Thomas Minor

Copyright © 2017 Cezary Chojnacki et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. G. B. J. Mancini, S. Baker, J. Bergeron et al., “Diagnosis, prevention, and management of statin adverse effects and intolerance: proceedings of a canadian working group consensus conference,” Canadian Journal of Cardiology, vol. 27, no. 5, pp. 635–662, 2011. View at Publisher · View at Google Scholar · View at Scopus
  2. L. Eslami, S. Merat, R. Malekzadeh, S. Nasseri-Moghaddam, and H. Aramin, “Statins for non-alcoholic fatty liver disease and non-alcoholic steatohepatitis,” The Cochrane Database of Systematic Reviews, vol. 27, no. 12, Article ID CD008623, 2013. View at Publisher · View at Google Scholar · View at Scopus
  3. M. Banach, M. Rizzo, P. P. Toth et al., “Statin intolerance – an attempt at a unified definition. Position paper from an international lipid expert panel,” Archives of Medical Science, vol. 11, no. 1, pp. 1–23, 2015. View at Publisher · View at Google Scholar
  4. D. R. Saxon and R. H. Eckel, “Statin intolerance: a literature review and management strategies,” Progress in Cardiovascular Diseases, vol. 59, no. 2, pp. 153–164, 2016. View at Publisher · View at Google Scholar
  5. B. B. Schalke, B. Schmidt, K. Toyka, H.-P. Hartung, T. A. Hayes, and L. M. Frau, “Pravastatin-associated inflammatory myopathy,” The New England Journal of Medicine, vol. 327, no. 9, pp. 649-650, 1992. View at Publisher · View at Google Scholar · View at Scopus
  6. M. Molokhia, P. McKeigue, V. Curcin, and A. Majeed, “Statin induced myopathy and myalgia: time trend analysis and comparison of risk associated with statin class from 1991–2006,” PLoS ONE, vol. 3, no. 6, Article ID e2522, 2008. View at Publisher · View at Google Scholar · View at Scopus
  7. R. Bitzur, H. Cohen, Y. Kamari, and D. Harats, “Intolerance to statins: mechanisms and management,” Diabetes Care, vol. 36, no. 2, pp. S325–S330, 2013. View at Publisher · View at Google Scholar · View at Scopus
  8. M. Thapar, M. Russo, and H. L. Bonkovsky, “Statins and liver injury,” Journal of Gastroenterology and Hepatology, vol. 9, no. 9, pp. 605-606, 2013. View at Google Scholar · View at Scopus
  9. J.-F. Cadranel, M. Seddik, S. Loric, and S. Jeanne, “Statins: hepatotoxicity and monitoring,” Presse Medicale, vol. 38, no. 5, pp. 717–725, 2009. View at Publisher · View at Google Scholar · View at Scopus
  10. J. Jose, “Statins and its hepatic effects: Newer data, implications, and changing recommendations,” Journal of Pharmacy and Bioallied Sciences, vol. 8, no. 1, pp. 23–28, 2016. View at Publisher · View at Google Scholar · View at Scopus
  11. N. Chalasani, H. Aljadhey, J. Kesterson, M. D. Murray, and S. D. Hall, “Patients with elevated liver enzymes are not at higher risk for statin hepatotoxicity,” Gastroenterology, vol. 126, no. 5, pp. 1287–1292, 2004. View at Publisher · View at Google Scholar · View at Scopus
  12. J. Armitage, “The safety of statins in clinical practice,” The Lancet, vol. 370, no. 9601, pp. 1781–1790, 2007. View at Publisher · View at Google Scholar · View at Scopus
  13. M. Arca and G. Pigna, “Treating statin-intolerant patients,” Diabetes, Metabolic Syndrome and Obesity, vol. 4, pp. 155–166, 2011. View at Publisher · View at Google Scholar
  14. R. M. Calderon, L. X. Cubeddu, R. B. Goldberg, and E. R. Schiff, “Statins in the treatment of dyslipidemia in the presence of elevated liver aminotransferase levels: a therapeutic dilemma,” Mayo Clinic Proceedings, vol. 85, no. 4, pp. 349–356, 2010. View at Publisher · View at Google Scholar · View at Scopus
  15. M. Shokrzadeh, A. Ahmadi, F. Naghshvar, A. Chabra, and M. Jafarinejhad, “Prophylactic efficacy of melatonin on cyclophosphamide-induced liver toxicity in mice,” BioMed Research International, vol. 2014, Article ID 470425, 6 pages, 2014. View at Publisher · View at Google Scholar · View at Scopus
  16. B. San-Miguel, I. Crespo, D. I. Sánchez et al., “Melatonin inhibits autophagy and endoplasmic reticulum stress in mice with carbon tetrachloride-induced fibrosis,” Journal of Pineal Research, vol. 59, no. 2, pp. 151–162, 2015. View at Publisher · View at Google Scholar · View at Scopus
  17. M.-M. Tiao, L.-T. Huang, C.-J. Chen et al., “Melatonin in the regulation of liver steatosis following prenatal glucocorticoid exposure,” BioMed Research International, vol. 2014, Article ID 942172, 9 pages, 2014. View at Publisher · View at Google Scholar · View at Scopus
  18. E. Esteban-Zubero, M. A. Alatorre-Jiménez, L. López-Pingarrón et al., “Melatonin's role in preventing toxin-related and sepsis-mediated hepatic damage: a review,” Pharmacological Research, vol. 105, pp. 108–120, 2016. View at Publisher · View at Google Scholar · View at Scopus
  19. J.-W. Kang, H.-I. Cho, and S.-M. Lee, “Melatonin inhibits mTOR-dependent autophagy during liver ischemia/reperfusion,” Cellular Physiology and Biochemistry, vol. 33, no. 1, pp. 23–36, 2014. View at Publisher · View at Google Scholar · View at Scopus
  20. S.-A. Gim and P.-O. Koh, “Melatonin attenuates hepatic ischemia through mitogen-activated protein kinase signaling,” Journal of Surgical Research, vol. 198, no. 1, pp. 228–236, 2015. View at Publisher · View at Google Scholar · View at Scopus
  21. H.-H. Chen, Y.-T. Chen, C.-C. Yang et al., “Melatonin pretreatment enhances the therapeutic effects of exogenous mitochondria against hepatic ischemia-reperfusion injury in rats through suppression of mitochondrial permeability transition,” Journal of Pineal Research, vol. 61, no. 1, pp. 52–68, 2016. View at Publisher · View at Google Scholar · View at Scopus
  22. E. A. Lane and H. B. Moss, “Pharmacokinetics of melatonin in man: first pass hepatic metabolism,” Journal of Clinical Endocrinology & Metabolism, vol. 61, no. 6, pp. 1214–1216, 1985. View at Publisher · View at Google Scholar
  23. R. J. Reiter, S. A. Rosales-Corral, L. C. Manchester, X. Liu, and D.-X. Tan, “Melatonin in the biliary tract and liver: health implications,” Current Pharmaceutical Design, vol. 20, no. 30, pp. 4788–4801, 2014. View at Publisher · View at Google Scholar · View at Scopus
  24. G. Facciolá, M. Hidestrand, C. Von Bahr, and G. Tybring, “Cytochrome P450 isoforms involved in melatonin metabolism in human liver microsomes,” European Journal of Clinical Pharmacology, vol. 56, no. 12, pp. 881–888, 2001. View at Publisher · View at Google Scholar · View at Scopus
  25. X. C. Ma, J. R. Idle, K. W. Krausz, and F. J. Gonzalez, “Metabolism of melatonin by human cytochromes P450,” Drug Metabolism and Disposition, vol. 33, no. 4, pp. 489–494, 2005. View at Publisher · View at Google Scholar · View at Scopus
  26. M. E. Letelier, J. Jara-Sandoval, A. Molina-Berríos, M. Faúndez, P. Aracena-Parks, and F. Aguilera, “Melatonin protects the cytochrome P450 system through a novel antioxidant mechanism,” Chemico-Biological Interactions, vol. 185, no. 3, pp. 208–214, 2010. View at Publisher · View at Google Scholar · View at Scopus
  27. C. Harthé, D. Claudy, H. Déchaud, B. Vivien-Roels, P. Pévet, and B. Claustrat, “Radioimmunoassay of N-acetyl-N-formyl-5-methoxykynuramine (AFMK): a melatonin oxidative metabolite,” Life Sciences, vol. 73, no. 12, pp. 1587–1597, 2003. View at Publisher · View at Google Scholar · View at Scopus
  28. A. Galano, D. X. Tan, and R. J. Reiter, “On the free radical scavenging activities of melatonin's metabolites, AFMK and AMK,” Journal of Pineal Research, vol. 54, no. 3, pp. 245–257, 2013. View at Publisher · View at Google Scholar · View at Scopus
  29. F. J. Akinrinmade, A. S. Akinrinde, and A. Amid, “Changes in serum cytokine levels, hepatic and intestinal morphology in aflatoxin B1-induced injury: modulatory roles of melatonin and flavonoid-rich fractions from Chromolena odorata,” Mycotoxin Research, vol. 32, no. 2, pp. 53–60, 2016. View at Publisher · View at Google Scholar · View at Scopus
  30. A. Laliena, B. S. Miguel, I. Crespo, M. Alvarez, J. González-Gallego, and M. J. Tuñón, “Melatonin attenuates inflammation and promotes regeneration in rabbits with fulminant hepatitis of viral origin,” Journal of Pineal Research, vol. 53, no. 3, pp. 270–278, 2012. View at Publisher · View at Google Scholar · View at Scopus
  31. G. Czechowska, K. Celinski, A. Korolczuk et al., “Protective effects of melatonin against thioacetamide-induced liver fibrosis in rats,” Journal of Physiology and Pharmacology, vol. 66, no. 4, pp. 567–579, 2015. View at Google Scholar · View at Scopus
  32. W. Hu, Z. Ma, S. Jiang et al., “Melatonin: the dawning of a treatment for fibrosis?” Journal of Pineal Research, vol. 60, no. 2, pp. 121–131, 2016. View at Publisher · View at Google Scholar
  33. J.-W. Kang, J.-M. Hong, and S.-M. Lee, “Melatonin enhances mitophagy and mitochondrial biogenesis in rats with carbon tetrachloride-induced liver fibrosis,” Journal of Pineal Research, vol. 60, no. 4, pp. 383–393, 2016. View at Publisher · View at Google Scholar · View at Scopus
  34. S. Shajari, A. Laliena, J. Heegsma, M. J. Tuñõn, H. Moshage, and K. N. Faber, “Melatonin suppresses activation of hepatic stellate cells through RORα-mediated inhibition of 5-lipoxygenase,” Journal of Pineal Research, vol. 59, no. 3, pp. 391–404, 2015. View at Publisher · View at Google Scholar · View at Scopus
  35. Y.-A. Cho, K. Noh, S.-S. Jue, S.-Y. Lee, and E.-C. Kim, “Melatonin promotes hepatic differentiation of human dental pulp stem cells: clinical implications for the prevention of liver fibrosis,” Journal of Pineal Research, vol. 58, no. 1, pp. 127–135, 2015. View at Publisher · View at Google Scholar · View at Scopus
  36. M. A. González, M. del Carmen Contini, N. Millen, and S. T. Mahieu, “Role of melatonin in the oxidative damage prevention at different times of hepatic regeneration,” Cell Biochemistry and Function, vol. 30, no. 8, pp. 701–708, 2012. View at Publisher · View at Google Scholar · View at Scopus
  37. H.-S. Choi, J.-W. Kang, and S.-M. Lee, “Melatonin attenuates carbon tetrachloride-induced liver fibrosis via inhibition of necroptosis,” Translational Research, vol. 166, no. 3, pp. 292–303, 2015. View at Publisher · View at Google Scholar · View at Scopus
  38. A. Stacchiotti, G. Favero, A. Lavazza et al., “Hepatic macrosteatosis is partially converted to microsteatosis by melatonin supplementation in ob/ob mice non-alcoholic fatty liver disease,” PLoS ONE, vol. 11, no. 1, Article ID e0148115, 2016. View at Publisher · View at Google Scholar · View at Scopus
  39. E. Björnsson, E. I. Jacobsen, and E. Kalaitzakis, “Hepatotoxicity associated with statins: reports of idiosyncratic liver injury post-marketing,” Journal of Hepatology, vol. 56, no. 2, pp. 374–380, 2012. View at Publisher · View at Google Scholar · View at Scopus
  40. S. H. Hussaini and E. A. Farrington, “Idiosyncratic drug-induced liver injury: an overview,” Expert Opinion on Drug Safety, vol. 6, no. 6, pp. 673–684, 2007. View at Publisher · View at Google Scholar · View at Scopus
  41. C. Ju and T. Reilly, “Role of immune reactions in drug-induced liver injury (DILI),” Drug Metabolism Reviews, vol. 44, no. 1, pp. 107–115, 2012. View at Publisher · View at Google Scholar · View at Scopus
  42. M. P. Holt and C. Ju, “Mechanisms of drug-induced liver injury,” AAPS Journal, vol. 8, no. 1, pp. E48–E54, 2006. View at Publisher · View at Google Scholar · View at Scopus
  43. S. Tujios and R. F. Fontana, “Mechanisms of drug-induced liver injury: from bedside to bench,” Nature Reviews Gastroenterology & Hepatology, vol. 8, no. 4, pp. 202–211, 2011. View at Publisher · View at Google Scholar
  44. M. W. Russo, M. Scobey, and H. L. Bonkovsky, “Drug-induced liver injury associated with statins,” Seminars in Liver Disease, vol. 29, no. 4, pp. 412–422, 2009. View at Publisher · View at Google Scholar · View at Scopus
  45. G. Stirnimann, K. Kessebohm, and B. Lauterburg, “Liver injury caused by drugs: an update,” Swiss Medical Weekly, vol. 140, Article ID 13080, 2010. View at Publisher · View at Google Scholar · View at Scopus
  46. A. Dash, R. A. Figler, A. J. Sanyal et al., “Drug-induced steatohepatitis,” Expert Opinion on Drug Metabolism & Toxicology, vol. 13, no. 2, pp. 193–204, 2017. View at Publisher · View at Google Scholar
  47. C. A. Dujovne, “Side effects of statins: hepatitis versus 'transaminitis'—Myositis versus 'CPKitis',” American Journal of Cardiology, vol. 89, no. 12, pp. 1411–1413, 2002. View at Publisher · View at Google Scholar · View at Scopus
  48. L. Tolosa, A. Carmona, J. V. Castell, M. J. Gómez-Lechón, and M. T. Donato, “High-content screening of drug-induced mitochondrial impairment in hepatic cells: effects of statins,” Archives of Toxicology, vol. 89, no. 10, pp. 1847–1860, 2015. View at Publisher · View at Google Scholar · View at Scopus
  49. K. M. Dale, C. M. White, N. N. Henyan, J. Kluger, and C. I. Coleman, “Impact of statin dosing intensity on transaminase and creatine kinase,” American Journal of Medicine, vol. 120, no. 8, pp. 706–712, 2007. View at Publisher · View at Google Scholar · View at Scopus
  50. E. V. Perdices, I. Medina-Cáliz, S. Hernando et al., “Hepatotoxicity associated with statin use: analysis of the cases included in the Spanish Hepatotoxicity Registry,” Revista Espanola De Enfermedades Digestivas, vol. 106, no. 4, pp. 246–254, 2014. View at Google Scholar · View at Scopus
  51. A. T. Clarke, P. C. D. Johnson, G. C. Hall, I. Ford, and P. R. Mills, “High dose atorvastatin associated with increased risk of significant hepatotoxicity in comparison to simvastatin in UK GPRD cohort,” PLoS ONE, vol. 11, no. 3, Article ID e0151587, 2016. View at Publisher · View at Google Scholar · View at Scopus
  52. M. H. Davidson and J. G. Robinson, “Safety of aggressive lipid management,” Journal of the American College of Cardiology, vol. 49, no. 17, pp. 1753–1762, 2007. View at Publisher · View at Google Scholar · View at Scopus
  53. N. G. Harpsøe, L. P. H. Andersen, I. Gögenur, and J. Rosenberg, “Clinical pharmacokinetics of melatonin: a systematic review,” European Journal of Clinical Pharmacology, vol. 71, no. 8, pp. 901–909, 2015. View at Publisher · View at Google Scholar · View at Scopus
  54. R. B. Costello, C. V. Lentino, C. C. Boyd et al., “The effectiveness of melatonin for promoting healthy sleep: a rapid evidence assessment of the literature,” Nutrition Journal, vol. 13, no. 1, article 106, 2014. View at Publisher · View at Google Scholar
  55. H. Huang, L. Jiang, L. Shen et al., “Impact of oral melatonin on critically ill adult patients with ICU sleep deprivation: study protocol for a randomized controlled trial,” Trials, vol. 15, no. 1, article 327, 2014. View at Publisher · View at Google Scholar · View at Scopus
  56. G. Klupińska, T. Poplawski, J. Drzewoski et al., “Therapeutic effect of melatonin in patients with functional dyspepsia,” Journal of Clinical Gastroenterology, vol. 41, no. 3, pp. 270–274, 2007. View at Publisher · View at Google Scholar · View at Scopus
  57. S. Mozaffari, R. Rahimi, and M. Abdollahi, “Implications of melatonin therapy in irritable bowel syndrome: a systematic review,” Current Pharmaceutical Design, vol. 16, no. 33, pp. 3646–3655, 2010. View at Publisher · View at Google Scholar · View at Scopus
  58. C. Chojnacki, E. Walecka-Kapica, K. Lokieć et al., “Influence of melatonin on symptoms of irritable bowel syndrome in postmenopausal women,” Endokrynologia Polska, vol. 64, no. 2, pp. 114–120, 2013. View at Google Scholar · View at Scopus
  59. K. T. H. Siah, R. K. M. Wong, and K. Y. Ho, “Melatonin for the treatment of irritable bowel syndrome,” World Journal of Gastroenterology, vol. 20, no. 10, pp. 2492–2498, 2014. View at Publisher · View at Google Scholar · View at Scopus
  60. G. Jena and P. P. Trivedi, “A review of the use of melatonin in ulcerative colitis: experimental evidence and new approaches,” Inflammatory Bowel Diseases, vol. 20, no. 3, pp. 553–563, 2014. View at Publisher · View at Google Scholar · View at Scopus
  61. A. A. Gelfand and P. J. Goadsby, “The role of melatonin in the treatment of primary headache disorders,” Headache Journals, vol. 56, no. 8, pp. 1257–1266, 2016. View at Publisher · View at Google Scholar · View at Scopus
  62. M. Gonciarz, Z. Gonciarz, W. Bielanski et al., “The pilot study of 3-month course of melatonin treatment of patients with nonalcoholic steatohepatitis: effect on plasma levels of liver enzymes, lipids and melatonin,” Journal of Physiology and Pharmacology, vol. 61, no. 6, pp. 705–710, 2010. View at Google Scholar · View at Scopus
  63. M. Gonciarz, Z. Gonciarz, W. Bielanski et al., “The effects of long-term melatonin treatment on plasma liver enzymes levels and plasma concentrations of lipids and melatonin in patients with nonalcoholic steatohepatitis: a pilot study,” Journal of Physiology and Pharmacology, vol. 63, no. 1, pp. 35–40, 2012. View at Google Scholar · View at Scopus
  64. H. Cichoz-Lach, K. Celinski, P. C. Konturek, S. J. Konturek, and M. Slomka, “The effects of l-tryptophan and melatonin on selected biochemical parameters in patients with steatohepatitis,” Journal of Physiology and Pharmacology, vol. 61, no. 5, pp. 577–580, 2010. View at Google Scholar · View at Scopus
  65. D. P. Cardinali and R. Hardeland, “Inflammaging, metabolic syndrome and melatonin: a call for treatment studies,” Neuroendocrinology, vol. 104, no. 4, pp. 382–397, 2016. View at Publisher · View at Google Scholar
  66. P. Schemmer, A. Nickkholgh, H. Schneider et al., “PORTAL: pilot study on the safety and tolerance of preoperative melatonin application in patients undergoing major liver resection: a double-blind randomized placebo-controlled trial,” BMC Surgery, vol. 8, article 2, 2008. View at Publisher · View at Google Scholar · View at Scopus
  67. A. Nickkholgh, H. Schneider, M. Sobirey et al., “The use of high-dose melatonin in liver resection is safe: first clinical experience,” Journal of Pineal Research, vol. 50, no. 4, pp. 381–388, 2011. View at Publisher · View at Google Scholar · View at Scopus
  68. L. P. H. Andersen, M. U. Werner, M. M. Rosenkilde et al., “Pharmacokinetics of high-dose intravenous melatonin in humans,” The Journal of Clinical Pharmacology, vol. 56, no. 3, pp. 324–329, 2016. View at Publisher · View at Google Scholar · View at Scopus
  69. L. P. H. Andersen, M. U. Werner, M. M. Rosenkilde et al., “Pharmacokinetics of oral and intravenous melatonin in healthy volunteers,” BMC Pharmacology and Toxicology, vol. 17, no. 1, article 8, 2016. View at Publisher · View at Google Scholar · View at Scopus
  70. N. S. Gooneratne, A. Y. Z. Edwards, C. Zhou, N. Cuellar, M. A. Grandner, and J. S. Barrett, “Melatonin pharmacokinetics following two different oral surge-sustained release doses in older adults,” Journal of Pineal Research, vol. 52, no. 4, pp. 437–445, 2012. View at Publisher · View at Google Scholar · View at Scopus
  71. F. Waldhauser, M. Waldhauser, H. R. Lieberman, M.-H. Deng, H. J. Lynch, and R. J. Wurtman, “Bioavailability of oral melatonin in humans,” Neuroendocrinology, vol. 39, no. 4, pp. 307–313, 1984. View at Publisher · View at Google Scholar · View at Scopus
  72. A. Korkmaz, T. Topal, D.-X. Tan, and R. J. Reiter, “Role of melatonin in metabolic regulation,” Reviews in Endocrine and Metabolic Disorders, vol. 10, no. 4, pp. 261–270, 2009. View at Publisher · View at Google Scholar · View at Scopus
  73. R. J. Reiter, D.-X. Tan, A. Korkmaz, and S. Ma, “Obesity and metabolic syndrome: association with chronodisruption, sleep deprivation, and melatonin suppression,” Annals of Medicine, vol. 44, no. 6, pp. 564–577, 2012. View at Publisher · View at Google Scholar · View at Scopus
  74. D. P. Cardinali, P. Cano, V. Jiménez-Ortega, and A. I. Esquifino, “Melatonin and the metabolic syndrome: physiopathologic and therapeutical implications,” Neuroendocrinology, vol. 93, no. 3, pp. 133–142, 2011. View at Publisher · View at Google Scholar · View at Scopus
  75. F. Nduhirabandi, E. F. du Toit, and A. Lochner, “Melatonin and the metabolic syndrome: a tool for effective therapy in obesity-associated abnormalities?” Acta Physiologica, vol. 205, no. 2, pp. 209–223, 2012. View at Publisher · View at Google Scholar · View at Scopus
  76. V. Srinivasan, Y. Ohta, J. Espino et al., “Metabolic syndrome, its pathophysiology and the role of melatonin,” Recent Patents on Endocrine, Metabolic & Immune Drug Discovery, vol. 7, no. 1, pp. 11–25, 2013. View at Publisher · View at Google Scholar · View at Scopus
  77. E. Walecka-Kapica, G. Klupińska, J. Chojnacki, K. Tomaszewska-Warda, A. Błońska, and C. Chojnacki, “The effect of melatonin supplementation on the quality of sleep and weight status in postmenopausal women,” Przeglad Menopauzalny, vol. 13, no. 6, pp. 334–338, 2014. View at Publisher · View at Google Scholar · View at Scopus
  78. S. S. Popov, K. K. Shulgin, T. N. Popova, A. N. Pashkov, A. A. Agarkov, and M. A. A. P. de Carvalho, “Effects of melatonin-aided therapy on the glutathione antioxidant system activity and liver protection,” Journal of Biochemical and Molecular Toxicology, vol. 29, no. 10, pp. 449–457, 2015. View at Publisher · View at Google Scholar · View at Scopus
  79. M. Koziróg, A. R. Poliwczak, P. Duchnowicz, M. Koter-Michalak, J. Sikora, and M. Broncel, “Melatonin treatment improves blood pressure, lipid profile, and parameters of oxidative stress in patients with metabolic syndrome,” Journal of Pineal Research, vol. 50, no. 3, pp. 261–266, 2011. View at Publisher · View at Google Scholar · View at Scopus
  80. A. Goyal, P. D. Terry, H. M. Superak et al., “Melatonin supplementation to treat the metabolic syndrome: a randomized controlled trial,” Diabetology and Metabolic Syndrome, vol. 6, Article ID 124, pp. 1–11, 2014. View at Publisher · View at Google Scholar · View at Scopus